Role of Osteopontin in Oral Epithelial Dysplasia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma

Overview

Journal J Oral Maxillofac Pathol

Date 2024 Feb 2

PMID 38304518

Authors

Nasir A Salati

Mohit Sharma

Nirmala N Rao

Smitha S Shetty

Raghu A Radhakrishnan

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory cells and cytokines in the chronically injured mucosa promote fibrosis in the oral submucous fibrosis (OSF) fibrotic milieu. Osteopontin (OPN) is a wound-healing mediator that upregulates the inflammatory response and is involved in the malignancy and fibrosis of multiple organ systems.

Objectives: We investigated the expression of OPN in oral potentially malignant disorders (OPMDs) and oral squamous cell carcinomas (OSCCs) to determine its role in the malignant transformation and fibrosis of oral tissues. The expression of OPN in OPMDs and OSCCs was compared and correlated, and the role of OPN as a fibrotic mediator in OSF was explained.

Study Design: A total of 30 cases of normal mucosa and OPMDs (mild dysplasia, severe dysplasia, OSF and OSCCs) were studied by purposive sampling. In these groups, OPN immunoreactivity was examined and correlated with clinical findings.

Results: In mild dysplasia, OPN expression was restricted to the basal cell layer with moderate staining intensity. In severe dysplasia, it was extremely intense and extended throughout the epithelium. In the OSF, OPN expression was moderate in the perinuclear areas of the basal cell layer. The expression of OPN was very strong in OSCC. A flow diagram explaining the profibrotic role of OPN in OSF has been provided.

Conclusion: A positive role of OPN in both pathogenesis and malignant transformation of OPMDs and OSCC has been demonstrated.

Citing Articles

Osteopontin as a prognostic biomarker in head and neck cancer- a systematic review and meta-analysis.

Piyarathne N, Hettiarachchi K, Yuwanati M, Sivaramakrishnan G, Ramanathan A, Jayasinghe R Evid Based Dent. 2025; .

PMID: 40074805 DOI: 10.1038/s41432-025-01133-8.

References

Khan I, Agarwal P, Thangjam G, Radhesh R, Rao S, Kondaiah P . Role of TGF-β and BMP7 in the pathogenesis of oral submucous fibrosis. Growth Factors. 2011; 29(4):119-27. DOI: 10.3109/08977194.2011.582839. View

Shimoda L, Fallon M, Pisarcik S, Wang J, Semenza G . HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol. 2006; 291(5):L941-9. DOI: 10.1152/ajplung.00528.2005. View

ORegan A, Nau G, Chupp G, Berman J . Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today. 2000; 21(10):475-8. DOI: 10.1016/s0167-5699(00)01715-1. View

Sharma M, Shetty S, Radhakrishnan R . Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation. Recent Pat Anticancer Drug Discov. 2018; 13(3):272-291. DOI: 10.2174/1574892813666180227103147. View

Banerjee A, Apte U, Smith R, Ramaiah S . Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease. J Pathol. 2006; 208(4):473-85. DOI: 10.1002/path.1917. View

Sodek J, Batista Da Silva A, Zohar R . Osteopontin and mucosal protection. J Dent Res. 2006; 85(5):404-15. DOI: 10.1177/154405910608500503. View

Klingberg F, Chau G, Walraven M, Boo S, Koehler A, Chow M . The fibronectin ED-A domain enhances recruitment of latent TGF-β-binding protein-1 to the fibroblast matrix. J Cell Sci. 2018; 131(5). PMC: 5897715. DOI: 10.1242/jcs.201293. View

Kothari A, Arffa M, Chang V, Blackwell R, Syn W, Zhang J . Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition. J Clin Med. 2016; 5(4). PMC: 4850462. DOI: 10.3390/jcm5040039. View

Zhu B, Suzuki K, Goldberg H, Rittling S, Denhardt D, McCulloch C . Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol. 2003; 198(1):155-67. DOI: 10.1002/jcp.10394. View

10.

Rybinski B, Franco-Barraza J, Cukierman E . The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics. 2014; 46(7):223-44. PMC: 4035661. DOI: 10.1152/physiolgenomics.00158.2013. View

11.

Herrero-Cervera A, Soehnlein O, Kenne E . Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022; 19(2):177-191. PMC: 8803838. DOI: 10.1038/s41423-021-00832-3. View

12.

Urtasun R, Lopategi A, George J, Leung T, Lu Y, Wang X . Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology. 2011; 55(2):594-608. PMC: 3561739. DOI: 10.1002/hep.24701. View

13.

Lech M, Anders H . Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim Biophys Acta. 2012; 1832(7):989-97. DOI: 10.1016/j.bbadis.2012.12.001. View

14.

Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch C . Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol. 2000; 184(1):118-30. DOI: 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y. View

15.

Hu D, Hoyer J, Smith J . Characterization of the interaction between integrins and recombinant human osteopontin. Ann N Y Acad Sci. 1995; 760:312-4. DOI: 10.1111/j.1749-6632.1995.tb44644.x. View

16.

Tuck A, OMalley F, Singhal H, Tonkin K, Harris J, Bautista D . Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med. 1997; 121(6):578-84. View

17.

Chen Z, Zhang N, Chu H, Yu Y, Zhang Z, Zhang G . Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery. Front Cell Dev Biol. 2020; 8:593269. PMC: 7658337. DOI: 10.3389/fcell.2020.593269. View

18.

Lee S, Yang S, Tsai C, Chou M, Chou M, Chang Y . Upregulation of heme oxygenase-1 expression in areca-quid-chewing-associated oral squamous cell carcinoma. J Formos Med Assoc. 2008; 107(5):355-63. DOI: 10.1016/S0929-6646(08)60100-X. View

19.

Reinholt F, Hultenby K, Oldberg A, Heinegard D . Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990; 87(12):4473-5. PMC: 54137. DOI: 10.1073/pnas.87.12.4473. View

20.

Beninati S, Senger D, Mukherjee A, Chackalaparampil I, Shanmugam V, Singh K . Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. J Biochem. 1994; 115(4):675-82. DOI: 10.1093/oxfordjournals.jbchem.a124395. View